1. Bubendorf, L., Tapia, C., Gasser, T.C., Casella, R., Grunder, B., Moch, H., Mihatsch, M.J. & Sauter, G. (1998) Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum. Pathol., 29, 949-954.
2. D’Amico, A.V., Whittington, R., Malkowicz, S., Schultz, D., Blank, K., Broderick, G.A., Tomaszewski, J.E., Renshaw, A.A., Kaplan, I., Beard, C.J. & Wein, A. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280, 969-974.
3. Dean, L.W., Assel, M., Sjoberg, D.D., Vickers, A.J., Al-Ahmadie, H.A., Chen, Y.B., Gopalan, A., Sirintrapun, S.J., Tickoo, S.K., Eastham, J.A., Scardino, P.T., Reuter, V.E., Ehdaie, B. & Fine, S.W. (2019) Clinical usefulness of total length of gleason pattern 4 on biopsy in men with grade group 2 prostate cancer. J. Urol., 201, 77-82.
4. Hakomori, S. (1996) Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res., 56, 5309-5318.
5. Hakomori, S. & Kannagi, R. (1983) Glycosphingolipids as tumor-associated and differentiation markers. J. Natl. Cancer Inst., 71, 231-251.